What is the comparative effectiveness and safety data for rivaroxaban vs dabigatran?
One systematic review and meta-analysis provided comparative effectiveness and safety data for rivaroxaban vs dabigatran (n 3 trials). Compared with dabigatran, rivaroxaban was associated with a signficantly higher risk of major bleeding (HR, 1.38; 95% CI, 1.27-1.49) but similar risk of any bleeding, mortality, acute MI, and ICH. Rivaroxaban was also associated with increased all-cause mortality and gastrointestinal bleeding compared to dabigatran.